Insiders Trades
Svas Biosana Stock: price and insider trades · Italy
Svas Biosana: what insiders have been doing
We have very little insider data for Svas Biosana so far: the most recent filing dates from 15 April 2025. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Svas Biosana Strong Buy (bullish), based on 1 analysts. Average price target: €12.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,678 of 24,148 companies
56.5
score / 100
Value64
Quality50
FCF yld-13%
Earn yld16%
EV/EBITDA6.4x
ROE10%
Gross mgn40%
Net mgn4.8%
Debt/EBITDA4.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€8.38
Analyst consensus
1 analystsStrong buy
€12.00Target €12.00(+43%)€12.00
Income statement
Revenue€141.5M
Gross profit€56.1M40% margin
EBITDA€19.1M13% margin
Net income€6.8M4.8% margin
Valuation
PER (trailing)6.5x
PER (forward)6.1x
P/Book0.7x
Beta0.95
Balance sheet & cash
Market cap€43.7M
Total debt€78.5M
Free Cash Flow-€5.7M
Debt / Equity113%
Profitability & ownership
ROE10.4%
ROA4.4%
% insiders70.4%
% institutions4.9%
Last declaration on 15 April 2025
About Svas Biosana
Svas Biosana is a company specialized in the healthcare and pharmaceutical sector. It is listed on the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
